TY - JOUR
T1 - The Community-Level Interventions for Pre-eclampsia (CLIP) cluster randomised trials in Mozambique, Pakistan, and India
T2 - an individual participant-level meta-analysis
AU - von Dadelszen, Peter
AU - Bhutta, Zulfiqar A.
AU - Sharma, Sumedha
AU - Bone, Jeffrey
AU - Singer, Joel
AU - Wong, Hubert
AU - Bellad, Mrutyunjaya B.
AU - Goudar, Shivaprasad S.
AU - Lee, Tang
AU - Li, Jing
AU - Mallapur, Ashalata A.
AU - Munguambe, Khátia
AU - Payne, Beth A.
AU - Qureshi, Rahat N.
AU - Sacoor, Charfudin
AU - Sevene, Esperança
AU - Vidler, Marianne
AU - Magee, Laura A.
AU - Macete, Eusébio
AU - Boene, Helena
AU - Amose, Felizarda
AU - Augusto, Orvalho
AU - Bique, Cassimo
AU - Biz, Ana Ilda
AU - Chiaú, Rogério
AU - Cutana, Silvestre
AU - Filimone, Paulo
AU - Gonçálves, Emília
AU - Macamo, Marta
AU - Macuacua, Salésio
AU - Maculuve, Sónia
AU - Mandlate, Ernesto
AU - Matavele, Analisa
AU - Mocumbi, Sibone
AU - Mulungo, Dulce
AU - Nhamirre, Zefanias
AU - Nhancolo, Ariel
AU - Nkumbula, Cláudio
AU - Nobela, Vivalde
AU - Pires, Rosa
AU - Tchavana, Corsino
AU - Vala, Anifa
AU - Vilanculo, Faustino
AU - Sheikh, Sana
AU - Hoodbhoy, Zahra
AU - Ahmed, Imran
AU - Hussain, Amjad
AU - Memon, Javed
AU - Raza, Farrukh
AU - Katageri, Geetanjali M.
AU - Charantimath, Umesh S.
AU - Bannale, Shashidhar G.
AU - Chougala, Keval S.
AU - Dhamanekar, Vaibhav B.
AU - Honnungar, Narayan V.
AU - Joshi, Anjali M.
AU - Kamble, Namdev A.
AU - Karadiguddi, Chandrappa C.
AU - Kavi, Avinash J.
AU - Kengapur, Gudadayya S.
AU - Kodkany, Bhalachandra S.
AU - Kudachi, Uday S.
AU - Mastiholi, Sphoorthi S.
AU - Mungarwadi, Geetanjali I.
AU - Ramdurg, Umesh Y.
AU - Revankar, Amit P.
AU - Drebit, Sharla K.
AU - Dunsmuir, Dustin T.
AU - Kariya, Chirag
AU - Lui, Mansun
AU - Sawchuck, Diane
AU - Tu, Domena K.
AU - Ukah, Ugochi V.
AU - Woo Kinshella, Mai Lei
AU - Ansermino, J. Mark
AU - Betrán, Ana Pilar
AU - Derman, Richard
AU - Dharamsi, Shafik
AU - Donnay, France
AU - Dumont, Guy
AU - Engelbrecht, Susheela M.
AU - Fillipi, Veronique
AU - Firoz, Tabassum
AU - Grobman, William
AU - Knight, Marian
AU - Langer, Ana
AU - Lewin, Simon
AU - Lewis, Gwyneth
AU - Mitton, Craig
AU - Schuurman, Nadine
AU - Shennan, Andrew
AU - Thornton, Jim
AU - Adetoro, Olalekan
AU - Sotunsa, John O.
N1 - Funding Information:
This study was funded by the University of British Columbia, a grantee of the Bill & Melinda Gates Foundation (OPP1017337). We thank the Government of Mozambique, Province of Sindh, and Government of India for their permission to integrate the CLIP trial into their health systems with in-kind support. We thank the families of the 143 women, 2591 fetuses, and 2677 neonates who died during the study period and who were willing to share their stories despite their grief. We particularly thank the following members of the Data Safety Monitoring Board: Romano Nkumbwa Byaruhanga, Brian Darlow, Eileen Hutton (Chair), and Lehana Thabane.
Funding Information:
This study was funded by the University of British Columbia, a grantee of the Bill & Melinda Gates Foundation (OPP1017337). We thank the Government of Mozambique, Province of Sindh, and Government of India for their permission to integrate the CLIP trial into their health systems with in-kind support. We thank the families of the 143 women, 2591 fetuses, and 2677 neonates who died during the study period and who were willing to share their stories despite their grief. We particularly thank the following members of the Data Safety Monitoring Board: Romano Nkumbwa Byaruhanga, Brian Darlow, Eileen Hutton (Chair), and Lehana Thabane.
Publisher Copyright:
© 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
PY - 2020/8/22
Y1 - 2020/8/22
N2 - Background: To overcome the three delays in triage, transport and treatment that underlie adverse pregnancy outcomes, we aimed to reduce all-cause adverse outcomes with community-level interventions targeting women with pregnancy hypertension in three low-income countries. Methods: In this individual participant-level meta-analysis, we de-identified and pooled data from the Community-Level Interventions for Pre-eclampsia (CLIP) cluster randomised controlled trials in Mozambique, Pakistan, and India, which were run in 2014–17. Consenting pregnant women, aged 12–49 years, were recruited in their homes. Clusters, defined by local administrative units, were randomly assigned (1:1) to intervention or control groups. The control groups continued local standard of care. The intervention comprised community engagement and existing community health worker-led mobile health-supported early detection, initial treatment, and hospital referral of women with hypertension. For this meta-analysis, as for the original studies, the primary outcome was a composite of maternal or perinatal outcome (either maternal, fetal, or neonatal death, or severe morbidity for the mother or baby), assessed by unmasked trial surveillance personnel. For this analysis, we included all consenting participants who were followed up with completed pregnancies at trial end. We analysed the outcome data with multilevel modelling and present data with the summary statistic of adjusted odds ratios (ORs) with 95% CIs (fixed effects for maternal age, parity, maternal education, and random effects for country and cluster). This meta-analysis is registered with PROSPERO, CRD42018102564. Findings: Overall, 44 clusters (69 330 pregnant women) were randomly assigned to intervention (22 clusters [36 008 pregnancies]) or control (22 clusters [33 322 pregnancies]) groups. 32 290 (89·7%) pregnancies in the intervention group and 29 698 (89·1%) in the control group were followed up successfully. Median maternal age of included women was 26 years (IQR 22–30). In the intervention clusters, 6990 group and 16 691 home-based community engagement sessions and 138 347 community health worker-led visits to 20 819 (57·8%) of 36 008 women (of whom 11 095 [53·3%] had a visit every 4 weeks) occurred. Blood pressure and dipstick proteinuria were assessed per protocol. Few women were eligible for methyldopa for severe hypertension (181 [1%] of 20 819) or intramuscular magnesium sulfate for pre-eclampsia (198 [1%]), of whom most accepted treatment (162 [89·5%] of 181 for severe hypertension and 133 [67·2%] of 198 for pre-eclampsia). 1255 (6%) were referred to a comprehensive emergency obstetric care facility, of whom 864 (82%) accepted the referral. The primary outcome was similar in the intervention (7871 [24%] of 32 290 pregnancies) and control clusters (6516 [22%] of 29 698; adjusted OR 1·17, 95% CI 0·90–1·51; p=0·24). No intervention-related serious adverse events occurred, and few adverse effects occurred after in-community treatment with methyldopa (one [2%] of 51; India only) and none occurred after in-community treatment with magnesium sulfate or during transport to facility. Interpretation: The CLIP intervention did not reduce adverse pregnancy outcomes. Future community-level interventions should expand the community health worker workforce, assess general (rather than condition-specific) messaging, and include health system strengthening. Funding: University of British Columbia, a grantee of the Bill & Melinda Gates Foundation.
AB - Background: To overcome the three delays in triage, transport and treatment that underlie adverse pregnancy outcomes, we aimed to reduce all-cause adverse outcomes with community-level interventions targeting women with pregnancy hypertension in three low-income countries. Methods: In this individual participant-level meta-analysis, we de-identified and pooled data from the Community-Level Interventions for Pre-eclampsia (CLIP) cluster randomised controlled trials in Mozambique, Pakistan, and India, which were run in 2014–17. Consenting pregnant women, aged 12–49 years, were recruited in their homes. Clusters, defined by local administrative units, were randomly assigned (1:1) to intervention or control groups. The control groups continued local standard of care. The intervention comprised community engagement and existing community health worker-led mobile health-supported early detection, initial treatment, and hospital referral of women with hypertension. For this meta-analysis, as for the original studies, the primary outcome was a composite of maternal or perinatal outcome (either maternal, fetal, or neonatal death, or severe morbidity for the mother or baby), assessed by unmasked trial surveillance personnel. For this analysis, we included all consenting participants who were followed up with completed pregnancies at trial end. We analysed the outcome data with multilevel modelling and present data with the summary statistic of adjusted odds ratios (ORs) with 95% CIs (fixed effects for maternal age, parity, maternal education, and random effects for country and cluster). This meta-analysis is registered with PROSPERO, CRD42018102564. Findings: Overall, 44 clusters (69 330 pregnant women) were randomly assigned to intervention (22 clusters [36 008 pregnancies]) or control (22 clusters [33 322 pregnancies]) groups. 32 290 (89·7%) pregnancies in the intervention group and 29 698 (89·1%) in the control group were followed up successfully. Median maternal age of included women was 26 years (IQR 22–30). In the intervention clusters, 6990 group and 16 691 home-based community engagement sessions and 138 347 community health worker-led visits to 20 819 (57·8%) of 36 008 women (of whom 11 095 [53·3%] had a visit every 4 weeks) occurred. Blood pressure and dipstick proteinuria were assessed per protocol. Few women were eligible for methyldopa for severe hypertension (181 [1%] of 20 819) or intramuscular magnesium sulfate for pre-eclampsia (198 [1%]), of whom most accepted treatment (162 [89·5%] of 181 for severe hypertension and 133 [67·2%] of 198 for pre-eclampsia). 1255 (6%) were referred to a comprehensive emergency obstetric care facility, of whom 864 (82%) accepted the referral. The primary outcome was similar in the intervention (7871 [24%] of 32 290 pregnancies) and control clusters (6516 [22%] of 29 698; adjusted OR 1·17, 95% CI 0·90–1·51; p=0·24). No intervention-related serious adverse events occurred, and few adverse effects occurred after in-community treatment with methyldopa (one [2%] of 51; India only) and none occurred after in-community treatment with magnesium sulfate or during transport to facility. Interpretation: The CLIP intervention did not reduce adverse pregnancy outcomes. Future community-level interventions should expand the community health worker workforce, assess general (rather than condition-specific) messaging, and include health system strengthening. Funding: University of British Columbia, a grantee of the Bill & Melinda Gates Foundation.
UR - http://www.scopus.com/inward/record.url?scp=85089488557&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(20)31128-4
DO - 10.1016/S0140-6736(20)31128-4
M3 - Article
C2 - 32828187
AN - SCOPUS:85089488557
SN - 0140-6736
VL - 396
SP - 553
EP - 563
JO - The Lancet
JF - The Lancet
IS - 10250
ER -